Literature DB >> 22658812

Validation of prognostic factors in malignant pleural mesothelioma: a retrospective analysis of data from patients seeking compensation from the New South Wales Dust Diseases Board.

Steven C Kao1, Janette Vardy, Mark Chatfield, Peter Corte, Nick Pavlakis, Christopher Clarke, Nico van Zandwijk, Stephen Clarke.   

Abstract

INTRODUCTION: We aimed to examine the prognostic values of established risk factors and to validate the prognostic value of the neutrophil-to-lymphocyte ratio (NLR) in an independent series of patients with malignant pleural mesothelioma (MPM). PATIENTS AND METHODS: A total of 148 patients who applied for compensation at the Dust Diseases Board from 2007 to 2009 were included in this study. Overall survival was determined by the Kaplan-Meier method, and NLR was defined as the absolute neutrophil divided by the lymphocyte count. The prognostic value of the variables was examined by using Cox regression analysis, and all factors were entered into a multivariate model to determine their independent effect.
RESULTS: The patient characteristics were median age of 73 years; 93% men; 59% epithelial subtype; median NLR of 3.5 at diagnosis (n = 79); median overall survival of 10.6 months. The following variables were predictive of longer overall survival in univariate analysis: younger age, epithelial subtype, lower tumor stage, low white cell count, low platelet count, low hemoglobin level, and low NLR. Multivariate analysis confirmed that nonepithelial vs. epithelial subtype (hazard ratio [HR], 3.0; P < .001), tumor stage (HR, 1.6; P < .001), hemoglobin level difference ≥10 vs. <10 (HR, 2.0; P = .03), no chemotherapy vs. use of chemotherapy (HR, 2.4; P < .001), and NLR ≥3 vs. <3 (HR, 2.2; P < .01) were independently associated with prognosis.
CONCLUSIONS: Apart from previously recognized factors, such as histosubtype, tumor stage, and hemoglobin level difference, NLR, an index of systemic inflammation bears prognostic significance that shows that a snapshot of immune status is able to convey important prognostic information.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22658812     DOI: 10.1016/j.cllc.2012.03.011

Source DB:  PubMed          Journal:  Clin Lung Cancer        ISSN: 1525-7304            Impact factor:   4.785


  29 in total

1.  Clinical role of a new prognostic score using platelet-to-lymphocyte ratio in patients with malignant pleural mesothelioma undergoing extrapleural pneumonectomy.

Authors:  Tetsuzo Tagawa; Masaki Anraku; Yosuke Morodomi; Tomoyoshi Takenaka; Tatsuro Okamoto; Mitsuhiro Takenoyama; Yukito Ichinose; Yoshihiko Maehara; B C John Cho; Ronald Feld; Ming-Sound Tsao; Natasha Leighl; Andrea Bezjak; Shaf Keshavjee; Marc de Perrot
Journal:  J Thorac Dis       Date:  2015-11       Impact factor: 2.895

2.  Radical surgery for malignant pleural mesothelioma: have we identified the appropriate selection tools?

Authors:  Nico van Zandwijk; Glen Reid; Anthony Linton; Steven Kao
Journal:  Ann Cardiothorac Surg       Date:  2012-11

3.  Biomarkers and prognostic factors for mesothelioma.

Authors:  Harvey I Pass
Journal:  Ann Cardiothorac Surg       Date:  2012-11

4.  Inflammation in malignant mesothelioma - friend or foe?

Authors:  Anthony Linton; Nico van Zandwijk; Glen Reid; Stephen Clarke; Christopher Cao; Steven Kao
Journal:  Ann Cardiothorac Surg       Date:  2012-11

5.  Plasma Biomarker Enrichment of Clinical Prognostic Indices in Malignant Pleural Mesothelioma.

Authors:  Harvey I Pass; Chandra Goparaju; Osvaldo Espin-Garcia; Jessica Donington; Michele Carbone; Devalben Patel; Zhuo Chen; Ronald Feld; John Cho; Shirish Gadgeel; Antoinette Wozniak; Abraham Chachoua; Natasha Leighl; Ming-Sound Tsao; Marc de Perrot; Wei Xu; Geoffrey Liu
Journal:  J Thorac Oncol       Date:  2016-02-21       Impact factor: 15.609

Review 6.  Diagnosis and prognosis-review of biomarkers for mesothelioma.

Authors:  Huan H Sun; Allen Vaynblat; Harvey I Pass
Journal:  Ann Transl Med       Date:  2017-06

7.  Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model.

Authors:  Chris J Weir; Amanda L Hudson; Lyndsay Peters; Viive M Howell
Journal:  J Vis Exp       Date:  2015-10-02       Impact factor: 1.355

8.  Prognostic value of parameters derived from white blood cell and differential counts in patients receiving palliative radiotherapy.

Authors:  Tetsuo Saito; Ryo Toya; Tomohiko Matsuyama; Akiko Semba; Keiya Matsuyama; Natsuo Oya
Journal:  Mol Clin Oncol       Date:  2016-07-22

9.  Prognostic value of the lymphocyte-to-monocyte ratio and other inflammatory markers in malignant pleural mesothelioma.

Authors:  Abdullah Cetin Tanrikulu; Abdurrahman Abakay; Halil Komek; Ozlem Abakay
Journal:  Environ Health Prev Med       Date:  2016-04-11       Impact factor: 3.674

10.  Serum albumin as a significant prognostic factor in patients with malignant pleural mesothelioma.

Authors:  Zhou-Hong Yao; Guang-Yan Tian; Shao-Xiang Yang; Yun-Yan Wan; Yan-Meng Kang; Qing-Hua Liu; Fei Yao; Dian-Jie Lin
Journal:  Tumour Biol       Date:  2014-04-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.